Financings in Brief: UroMed
This article was originally published in The Gray Sheet
UroMed: Files registration statement with the Securities and Exchange Commission for a secondary offering of 2.5 mil. shares, all of which are being offered by the company. On Oct. 18, the day the plans were announced, the issue closed at $10 a share. PaineWebber and Vector Securities International are managing the offering. Multi-center interim study results of the firm's first product, the Reliance female urinary incontinence device ("The Gray Sheet" Sept. 11, p. 10), were presented Oct. 12 at the American Urogynecologic Society annual scientific meeting ("The Gray Sheet" Oct. 16, In Brief). In its third quarter (ended Sept. 30), UroMed recorded its first-ever revenues of $404,662, which included sales of the Reliance device in Germany. UroMed booked a loss of $2.3 mil. for the period...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.